3.1 Subject disposition and baseline characteristics
There were 18 subjects enrolling in this study. All 18 subjects
completed the phase of a single dose of SHR2554 and the phase of
multiple doses of rifampin. 17 subjects completed the coadministration
of SHR2554 and rifampin, and 1 subject withdrew from the study due to
AEs. All 18 subjects who received investigation drug were included in
the safety set and PK concentration set. The subject disposition and
baseline characteristics were shown in Table 1.